Aditx Therapeutics Stock Is Trading Higher On Initiating Human Trials With Psoriasis Candidate By 2021
Aditx Therapeutics Inc (NASDAQ: ADTX) is preparing its therapeutic program for psoriasis for First-In-Human clinical trials by the end of this year.
The trials, which are planned to begin in Q4 2021, will evaluate the clinical safety and efficacy of Aditxt's new approach to reprogramming and retraining the immune system.
The trials will evaluate the clinical safety and efficacy of a nucleic acid-based technology named Apoptotic DNA Immunotherapy (ADi).
Aditxt's ADi technology utilizes an approach that mimics how the body naturally induces tolerance to its tissues (therapeutically induced immune tolerance).
ADi has demonstrated efficacy in several pre-clinical disease models, including psoriasis, in which a reduction in skin thickening and scaling and modulation of crucial protein markers were observed.
The firm will work with a regulatory consultant in Germany to submit an Investigational New Drug Application to Germany's regulatory agency.
Psoriasis is the first indication being targeted for a clinical trial. Other candidates that are advancing toward clinical trials include ADi for type 1 diabetes and skin allografting.
Price Action: ADTX shares are trading 7.94% higher at $3.40 in premarket trading on the last check Wednesday.
See more from Benzinga
Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study
Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
